ProfileGDS5678 / 1424694_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 73% 75% 74% 76% 73% 76% 75% 78% 75% 75% 75% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9814675
GSM967853U87-EV human glioblastoma xenograft - Control 24.723873
GSM967854U87-EV human glioblastoma xenograft - Control 34.975375
GSM967855U87-EV human glioblastoma xenograft - Control 44.9880174
GSM967856U87-EV human glioblastoma xenograft - Control 55.1502976
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5849173
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9691776
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.9595875
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.3259878
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.969975
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.9625975
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.9795875
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9752775
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.966875